Welcome to our dedicated page for Aspira Women's Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women's Health stock.
Aspira Women's Health Inc. (Nasdaq: AWH) is a pioneering company focused on the development and commercialization of noninvasive diagnostic tests for gynecologic diseases. The company is at the forefront of women's health, offering innovative solutions that leverage bio-analytical techniques and artificial intelligence.
One of Aspira's flagship products is OvaSuite, a comprehensive portfolio of blood tests designed to assess the risk of ovarian cancer. This suite includes the well-known OvaWatch and Ova1Plus tests. OvaWatch, with a negative predictive value of 99%, is instrumental in evaluating ovarian cancer risk in women with adnexal masses that appear indeterminate or benign, potentially allowing them to avoid unnecessary surgeries. Ova1Plus combines two FDA-cleared tests, Ova1® and Overa®, providing a robust assessment for women scheduled for surgery due to pelvic masses.
In addition to ovarian cancer diagnostics, Aspira is expanding its test pipeline to address other pressing women's health issues. The company is developing EndoCheck, the first-ever noninvasive test for identifying endometriomas, a common form of endometriosis. Another promising test in development is OvaMDx, which combines microRNA and protein biomarkers with patient data to enhance the accuracy of ovarian cancer risk assessments.
The company's commitment to innovation is reflected in its recent achievements. Aspira has published significant clinical studies demonstrating the efficacy of OvaWatch in longitudinal monitoring of ovarian cancer risk, which could significantly reduce surgical backlogs and unnecessary referrals. Furthermore, Aspira has made strides in market access, securing payer coverage from Anthem Blue Cross and expanding its reach to millions of lives across various health plans.
Financially, Aspira has shown remarkable progress. In 2023, the company significantly reduced its operational cash use while increasing revenues and test volumes. These accomplishments were accompanied by important enhancements to their commercial organization and the achievement of key market access milestones. As of December 31, 2023, Aspira had $2.9 million in cash and raised an additional $5.5 million through a registered direct offering and private placement.
The management team, led by CEO Nicole Sandford, has positioned Aspira for substantial growth in 2024 and beyond. The company's forward-looking strategies and robust test pipeline are set to meet the growing demand for noninvasive diagnostics in women's health, offering new hope and improved outcomes for millions of women worldwide.
Aspira Women’s Health (Nasdaq: AWH) will participate in the 10th Annual LifeSci Advisors Corporate Access Event from January 6-8 and 11-14, 2021, along with the 2021 Biotech Showcase from January 11-15. Management, including President Valerie Palmieri and CFO Robert Beechey, will hold 1x1 meetings and present on Innovations in Cancer Diagnostics on January 7. The conference aims to foster investor relationships and partnerships in therapeutic development. More details and registration links are available in the full announcement.
Aspira Women's Health, Inc. (Nasdaq: AWH) has partnered with Baylor Genetics to co-develop a novel early-detection test for ovarian cancer, which has a mortality rate exceeding 50%. This collaboration aims to leverage both companies' strengths, focusing on the OVA360 clinical study to establish an ovarian cancer molecular profile. Aspira brings over a decade of experience in ovarian cancer detection and has developed multiple FDA-cleared products, while Baylor Genetics contributes advanced genomic testing expertise. The partnership seeks to enhance early detection and improve clinical outcomes for women.
Aspira Women’s Health Inc. (AWH) reported strong financial results for Q3 2020, with product revenue of $1.2 million, a 68% increase from Q2 2020. Test volume has rebounded to 95% of pre-COVID levels, aided by a new CIGNA contract, expanding payer coverage, and an increase in pricing. OVA1 test volume grew 46% sequentially, and 84% of its customers were repeat physicians. The company added key executives to its leadership team, emphasizing its commitment to women's health. Cash balance stood at approximately $19 million.
Aspira Women’s Health appoints five new executives to enhance its focus on women’s health and tackle ovarian cancer. The new leadership team includes experienced professionals from various healthcare sectors, aiming to accelerate innovation and growth. Notable appointments include Dr. Elena Ratner as Global Chief Medical Advisor and Kaile Zagger as Chief Operating Officer. The company seeks to improve gynecologic cancer detection and risk management, aligning with its mission to support women of all backgrounds. Aspira’s advancements position it favorably in the growing market for cancer diagnostics.
Aspira Women’s Health, Inc. (Nasdaq: AWH) has appointed Dr. Sandra E. Brooks to its Board of Directors, enhancing its leadership team amid growth. With a strong background as a gynecologic oncologist and physician executive, Dr. Brooks brings valuable insights to the company as it aims to expand into larger healthcare systems and address gynecologic diseases. This change increases the Board's female representation to a majority, reflecting the company's commitment to diversity. Aspira focuses on innovative testing solutions to improve women's health, particularly in ovarian cancer risk assessment.
Aspira Women’s Health, Inc. (Nasdaq: AWH) announced its participation in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 9:00 AM ET. The presentation will be webcast live, with registration details available on their website. Aspira is focused on innovative testing for women’s health, specifically in ovarian cancer risk assessment and pelvic diseases. Their product portfolio includes FDA-cleared options like OVA1® and OVERA®. The company aims to address ethnic disparities in health outcomes through advanced bioanalytical solutions.
Aspira Women’s Health, Inc. (AWH) is set to report its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020, after market close. An investor conference call will follow at 4:30 p.m. ET. The company focuses on innovative testing solutions for women's health, particularly in ovarian cancer risk assessment and pelvic disease management. Aspira is positioned to address ethnic disparities in health outcomes through its product portfolio, including OVA1 plus and ASPIRA GenetiX testing.
Aspira Women’s Health Inc. (Nasdaq: AWH) announces a significant expansion of network access for its OVA1® and ASPIRA GenetiX® testing, now serving approximately 3.3 million members of Anthem BlueCross BlueShield of Georgia. This partnership allows Aspira to reach nearly 30% of Georgia’s population, enhancing access to crucial ovarian cancer risk assessment tools. The company is committed to addressing ethnic disparities in ovarian cancer, focusing on delivering innovative testing solutions for women across various demographics.
Aspira Women’s Health, Inc. (Nasdaq: AWH) has been invited to present at the MicroCap Rodeo Best Ideas Bowl, occurring virtually from October 13-16, 2020. The company’s presentation is scheduled for October 14 from 11:30-11:55 am EST, and will be available for live streaming and replay. Aspira focuses on innovative testing solutions for women’s health, specifically addressing ovarian cancer risk assessment and pelvic diseases. Interested parties can register for the webcast or one-on-one meetings via the provided links.
Aspira Women’s Health (Nasdaq: AWH) will host a key opinion leader (KOL) call on September 25, 2020, at 12:00 PM ET, to discuss ovarian cancer diagnostics and their innovation pipeline. KOLs Dr. Christopher Bryant and Dr. Gerard P. Reilly will present insights on current diagnostics, treatment options, and AWH’s clinical studies. The management team will also share details on their rebranding initiatives and products like OVA1 plus. Interested parties can register.
FAQ
What is the current stock price of Aspira Women's Health (AWH)?
What is the market cap of Aspira Women's Health (AWH)?
What is Aspira Women's Health Inc. known for?
What products does Aspira offer?
How effective is OvaWatch?
What is Ova1Plus?
What recent achievements has Aspira made?
What is EndoCheck?
How has Aspira performed financially recently?
Who leads Aspira Women's Health Inc.?
What is OvaMDx?
How does Aspira's test pipeline address women's health issues?
